NCT04023994View on ClinicalTrials.gov

A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 3, 2019

Primary Completion Date

July 17, 2020

Study Completion Date

July 17, 2020

Conditions
Alzheimers Disease
Interventions
DRUG

RO7126209

Participants will be administered single-ascending intravenous doses of RO7126209 with at least 2 weeks between each dose level. After the starting dose, the subsequent doses will be selected in an adaptive design. Sentinel dosing will be employed.

DRUG

Placebo

Participants will be administered a single intravenous dose of matching placebo.

Trial Locations (1)

27612

PRA Health Sciences, Raleigh

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT04023994 - A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants | Biotech Hunter | Biotech Hunter